Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
1 ratings / 4 average

Endothelial Progenitor Cells as a Target for Therapy of Pulmonary Hypertension

Laszlo Farkas, MD1,2,3, and Martin R Kolb, MD, PhD1,2

Pulmonary hypertension (PH) is characterized by elevated pulmonary vascular pressure and resistance, which is associated with increased pressure in the pulmonary arterial and/or venous system [1]. Various conditions can underlie the development of PH, such as connective tissue disease, which leads to pulmonary arterial hypertension (PAH), but also myocardial or heart valve disease, resulting in pulmonary venous hypertension [1]. In a large subgroup of patients with PAH, the origin of the disease is unknown (defined as idiopathic PAH [IPAH]). Furthermore, a broad variety of chronic pulmonary diseases are associated with PH, including chronic obstructive pulmonary disease (COPD), interstitial lung disease, obstructive sleep apnea, and bronchopulmonary dysplasia [1]. Chronic thromboembolic disease is a major cause of PH, and is also included in the classification of PH [1]. 


Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles